3-Deoxy-2β,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cells
Authors:
- 14 June 2019
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 40 (12) , 1578-1586
Abstract
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways, especially the JAK2/STAT3 pathway, play vital roles in the development of many malignancies. Overactivation of STAT3 promotes cancer cell survival and proliferation. Therefore, the JAK2/STAT3-signaling pathway has been considered a promising target for cancer therapy. In this study, we identified a natural compound 3-deoxy-2β,16-dihydroxynagilactone E (B6) from the traditional Chinese medicinal plant Podocarpus nagi as a potent inhibitor of STAT3 signaling. B6 preferentially inhibited the phosphorylation of STAT3 by interacting with and inactivating JAK2, the main upstream kinase of STAT3. B6 dose-dependently inhibited IL-6-induced STAT3 signaling with an IC50 of 0.2 μM. In contrast to other JAK2 inhibitors, B6 did not interact with the catalytic domain but instead with the FERM-SH2 domain of JAK2. This interaction was JAK-specific since B6 had little effect on other tyrosine kinases. Furthermore, B6 potently inhibited the growth and induced apoptosis of MDA-MB-231 and MDA-MB-468 breast cancer cells with overactivated STAT3. Taken together, our study uncovers a novel compound and a novel mechanism for the regulation of JAK2 and offers a new therapeutic approach for the treatment of cancers with overactivated JAK2/STAT3.Keywords
This publication has 47 references indexed in Scilit:
- Regulation of JAK2 Activation by Janus Homology 2: Evidence from Molecular Dynamics SimulationsJournal of Chemical Information and Modeling, 2012
- Suppressors of Cytokine Signaling (SOCS) Proteins and JAK/STAT PathwaysArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat PathwayJournal of Medicinal Chemistry, 2010
- 17-Hydroxy-jolkinolide B Inhibits Signal Transducers and Activators of Transcription 3 Signaling by Covalently Cross-Linking Janus Kinases and Induces Apoptosis of Human Cancer CellsCancer Research, 2009
- Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptorsOncogene, 2000
- The Janus kinase family of protein tyrosine kinases and their role in signalingCellular and Molecular Life Sciences, 1999
- Regulation of the Jak/STAT signalling pathwayCellular Signalling, 1995
- The Janus Kinase Family and Signaling Through Members of the Cytokine Receptor SuperfamilyExperimental Biology and Medicine, 1994
- Cytokine signal transduction and the JAK family of protein tyrosine kinasesBioEssays, 1994
- Combination Effects of Antifungal Nagilactones Against Candida albicans and Two Other Fungi with PhenylpropanoidsJournal of Natural Products, 1993